Human Microbiome Inspired Antibiotics with Improved β-Lactam Synergy against MDR Staphylococcus aureus

John Chu, Xavier Vila-Farres, Daigo Inoyama, Ricardo Gallardo-Macias, Mark Jaskowski, Shruthi Satish, Joel S. Freundlich, Sean F. Brady

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The flippase MurJ is responsible for transporting the cell wall intermediate lipid II from the cytoplasm to the outside of the cell. While essential for the survival of bacteria, it remains an underexploited target for antibacterial therapy. The humimycin antibiotics are lipid II flippase (MurJ) inhibitors that were synthesized on the basis of bioinformatic predictions derived from secondary metabolite gene clusters found in the human microbiome. Here, we describe an SAR campaign around humimycin A that produced humimycin 17S. Compared to humimycin A, 17S is a more potent β-lactam potentiator, has a broader spectrum of activity, which now includes both methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococcus faecalis (VRE), and did not lead to any detectable resistance when used in combination with a β-lactam. Combinations of β-lactam and humimycin 17S provide a potentially useful long-term MRSA regimen.

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalACS infectious diseases
Volume4
Issue number1
DOIs
StatePublished - Jan 12 2018

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Keywords

  • MRSA
  • NRPS
  • Syn-BNP
  • antibiotics
  • β-lactam

Fingerprint

Dive into the research topics of 'Human Microbiome Inspired Antibiotics with Improved β-Lactam Synergy against MDR Staphylococcus aureus'. Together they form a unique fingerprint.

Cite this